Credit score: Pixabay/CC0 Public Area
Crizotinib, an permitted remedy for superior ALK-positive (ALK+) non-small cell lung most cancers (NSCLC), didn’t enhance disease-free survival (DFS) when given as adjuvant remedy in sufferers with surgically resected early-stage ALK+ NSCLC, in accordance with outcomes from the Section II E4512 trial offered on the Worldwide Affiliation for the Research of Lung Most cancers (IASLC) 2025 World Convention on Lung Most cancers (WCLC).
The trial, performed throughout the ALCHEMIST medical trials program, enrolled sufferers with resected stage IIA–IIIB (AJCC eighth version) ALK+ NSCLC confirmed by FISH, IHC, or NGS. Eligible sufferers had unfavourable surgical margins, an ECOG efficiency standing of 0–1, and no prior ALK inhibitor remedy. Adjuvant chemotherapy and post-operative radiation remedy have been permitted.
David Gerber, MD, a medical oncologist on the UT Southwestern Harold C. Simmons Complete Most cancers Heart, and colleagues randomized sufferers to obtain remark or crizotinib 250 mg twice every day for as much as two years, or till illness recurrence or unacceptable toxicity. The first endpoint was DFS, with secondary endpoints of general survival (OS) and security.
Between August 2014 and Might 2024, 166 sufferers (of 168 deliberate) have been enrolled (92% confirmed centrally as ALK+). Enrollment was stopped after the U.S. Meals and Drug Administration permitted adjuvant alectinib for resected ALK+ NSCLC.
At a median follow-up of 58.3 months, the research discovered that:
Median DFS was 72.8 months for crizotinib vs. 75.1 months for remark (HR 1.06; 90% CI, 0.63–1.77; P=0.86).
Median OS was not reached in both arm (HR 0.49; 90% CI, 0.18–1.37; P=0.26).
Grade 3 treatment-related hostile occasions occurred in 34% of sufferers receiving crizotinib, mostly diarrhea (6%) and edema (4%); one affected person skilled a grade 4 occasion (stroke).
22% of sufferers required dose reductions and 25% discontinued remedy attributable to toxicity.
“Adjuvant crizotinib does not prolong disease-free survival in resected ALK+ NSCLC,” stated Dr. Gerber.
Supplied by
Worldwide Affiliation for the Research of Lung Most cancers
Quotation:
Crizotinib fails to enhance disease-free survival in resected early-stage ALK+ non-small cell lung most cancers (2025, September 7)
retrieved 7 September 2025
from https://medicalxpress.com/information/2025-09-crizotinib-disease-free-survival-resected.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
